The funneling of wealth to the top has been due to tax payer subsidies, tax breaks and corporate welfare to concentrated corporate interests and tax breaks for the wealthiest Americans.
This variable is also more readily considered in practice settings where insurance status is not an issue due to single-payer health systems.
The introduction of biosimilar medicines has the potential to provide cost competition and reduce cost to the payer due to their lower development costs [ 27].
However, when scaled up to a system wide level, SVR translates into substantial direct cost-savings for the payer due to costly complications avoided, as well as lower indirect costs due to lost productivity through absenteeism and presenteeism.
As for my Lynch-based model, it considers AGL a "slow-grower"/ dividend-payer," due to its steady-as-she-goes 5.28% long-term growth rate and stellar 5.44% dividend yield.
Furthermore, as erlotinib shows a more favorable tolerability profile the costs of treating adverse events are lower for erlotinib than for the cytotoxic chemotherapy, which again results in additional effort for health care payers due to docetaxel.
In the private sector it is relatively more complex due to the multiplicity of payers (around 1500 health plans) and providers (around 300, 000 including hospitals, laboratories, physicians and dentists) with different billing rules.
Community-based dementia care is cost saving from the payer perspective due to substantially lower long-term care expenditures.
The special nature of pharmaceutical markets (due to patent protection, third-party payers and low price elasticity) has led to the introduction of regulation in European markets.
Thus, as hospitals gain market power (as their HHI goes up), the quality of care may fall due to competition for patients whose payers pay fixed, non-negotiable fees.
